 Atopic dermatitis is one of the most common skin diseases, with a lifetime prevalence of up to 20, and an increasing number of cases. Although there are a variety of treatments the number of specific medications for treating this chronic disease is limited and often not helpful, especially in more severe cases. In addition,most treatments may be used only for a limited period or are less effective in the long term tachyphylaxis. The development of new compounds is mandatory for treatment of this often chronically recurring disease. The current trial will determine the efficacy, safety and tolerability of the endogenous compound imidazole-4-carboxylic acid ImCOOH administered as a topical cream twice daily for 14 days in patients with atopic dermatitis. 